Catalyst Biosciences Announces Proposed Public Offering of Common Stock
February 12 2018 - 4:33PM
Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage
biopharmaceutical company focused on developing novel medicines to
address hematology indications (the Company), today announced that
it is offering, subject to market conditions, shares of its common
stock in an underwritten public offering. The Company anticipates
using the net proceeds from this offering for general corporate
purposes, which may include clinical and manufacturing activities
for CB 2679d and Marzeptacog alfa (activated), research and
development activities, capital expenditures, selling, general and
administrative costs, facilities expansion, and to meet working
capital needs. All of the shares in the offering are to be sold by
the Company.JonesTrading Institutional Services LLC is acting as
Sole Bookrunning Manager, Ladenburg Thalmann & Co. Inc., a
subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE
American:LTS) is acting as Joint Bookrunner and LifeSci Capital LLC
is acting as a Lead Manager for the proposed offering.
A shelf registration statement on Form S-3
relating to the public offering of the shares of common stock
described above was filed with the Securities and Exchange
Commission (SEC) and is effective. A preliminary prospectus
supplement relating to the offering will be filed with the SEC and
will be available on the SEC’s web site at www.sec.gov. When
available, copies of the preliminary prospectus supplement may also
be obtained from JonesTrading Institutional Services LLC, 32133
Lindero Canyon Road, Suite 208, Westlake Village, CA 91361,
Attention: Compliance Department, or via telephone at (844)
566-6587 or via email at syndicate@jonestrading.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy any of the
securities described herein. There shall not be any offer,
solicitation of an offer to buy, or sale of securities in any state
or jurisdiction in which such an offering, solicitation, or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About
Catalyst
Catalyst is a clinical-stage biopharmaceutical
company developing novel medicines to address hematology
indications. Catalyst is focused on the field of hemostasis,
including the subcutaneous prophylaxis of hemophilia and
facilitating surgery in individuals with hemophilia.
Forward-Looking
Statements
This press release contains forward-looking
statements that involve substantial risks and uncertainties. All
statements pertaining to the Company’s expectations regarding the
completion, timing, pricing and size of the offering described in
this press release constitute forward-looking statements. All
statements, other than statement of historical facts (including,
but not limited to, statements that contain words such as “will,”
“believes,” “plans,” “anticipates,” “expects,” “estimates”) are
forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various important
factors could cause actual results or events to differ materially
from the forward-looking statements that the Company makes,
including, but not limited to, the risk that trials and studies may
be delayed and may not have satisfactory outcomes, that human
trials will not replicate the results from animal studies, that
potential adverse effects may arise from the testing or use of the
Company’s products, including the generation of antibodies, the
risk that costs required to develop or manufacture the Company’s
products will be higher than anticipated, competition and other
factors that affect our ability to establish collaborations on
commercially reasonable terms and other risks described in the
“Risk Factors” section of the Company’s Annual Report on Form 10-K
for the year ended December 31, 2016 and the Company’s Quarterly
Reports on Form 10-Q for the quarters ended March 31, 2017, June
30, 2017, and September 30, 2017 along with other filings with the
Securities and Exchange Commission. The Company does not assume any
obligation to update any forward-looking statements, except as
required by law.
Contacts:
Investors:
Fletcher Payne, CFOCatalyst Biosciences,
Inc.1.650.871.0761investors@catbio.com
Media:
Josephine Belluardo, Ph.D.LifeSci Public
Relations1.646.751.4361jo@lifescipublicrelations.com
Source: Catalyst Biosciences, Inc.
Ladenburg Thalmann Finan... (AMEX:LTS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ladenburg Thalmann Finan... (AMEX:LTS)
Historical Stock Chart
From Sep 2023 to Sep 2024